Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.
about
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionTenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.Pharmacokinetics of antiretrovirals in mucosal tissueGenomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentCompared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing studyTenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsHigher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.Clinical pharmacokinetics of antiretroviral drugs in older persons.Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Plasma and Intracellular Pharmacokinetics of Tenofovir in Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.Subcellular drug targeting, pharmacokinetics and bioavailability.Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART
P2860
Q28481276-0D270EED-F667-498A-BEE2-B3E98B778209Q34034418-F6CCE61F-6116-4260-9F70-0242F6183C93Q34658079-5280C639-CFC8-446C-88C1-6BB1384A06C6Q35668556-CC1C84DC-7C1B-49FF-9B3B-99872B00C12FQ35812127-271744DA-5B2E-4E38-A502-7F08DE1E6EAAQ35838594-EF8FFFAD-9705-4066-B6C1-E3CCE9E25E42Q35908584-08D1362B-3DEC-4C7C-A3E4-9257509DA537Q36075954-68D0027F-41A5-4146-BD2D-D21D729130EAQ36167503-2ED91036-4C97-46C7-B1BA-55D75862842EQ36172455-9849DFFD-0ED3-42A5-BD1D-A0133710F418Q36188725-D5398C1C-1BA9-4F94-AA1F-8820E76FDA8AQ36432228-698B02BC-6F21-4BC0-B06D-64D129DFE14EQ36554980-50DF3B1D-17D6-4D1F-ADF0-3358F7AEBF72Q36650454-1E723573-82B6-4665-8873-695F297185C7Q36663586-BA36B6A2-4121-41AC-AC02-966329A83677Q36739989-116A97D4-BBC8-4BB8-BEED-31A85AFB9661Q36905884-6B1DE06D-E7FA-452C-B5D1-BD4EF0459036Q37042094-6255BCE2-FE49-411D-86B0-AAB65C674BBCQ37203867-34B8EF8B-1286-4374-B2EE-5118D18C1BE8Q37210864-E52675BA-4F1D-4A9A-ADE3-FC262F70C8FBQ37224902-ED47A3C6-34F6-4098-9AE6-E31A6FEA68AFQ37587740-8720AFB6-D4D5-4260-A607-5552943F4315Q37641171-10BB0700-5820-4B10-B560-E62287852B11Q37713065-EF91F602-0FB0-4C49-AB34-56E0B3389741Q38750666-80C9B2A2-8274-49E2-84F6-98D54FAFCF26Q38755666-BB42CED8-F8F2-4DA3-8347-27EC22B64019Q39434360-AA6E920D-1FB5-4DD9-A71E-3A727676365CQ40181126-8DE3D1B8-B17F-495A-8B08-D7AAC900086AQ40462001-A68B0792-8308-49FE-9C92-09EB1A95C451Q42279687-DE335F72-AEA7-4760-BD9A-3B5DFFB28C14Q47628152-FFE3FEC2-DB5E-4159-992F-3555074F18B7Q47633560-6277644A-A6DF-4A6A-B6D0-31631442EFF7Q48506430-372CEBE1-347D-4D17-9C5D-9AACF8090E0BQ54665069-07453D08-C1AD-4537-BA1C-D2D6DB522B0EQ58538219-9AD6B24F-396E-4019-B632-571F73527F4B
P2860
Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@ast
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@en
type
label
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@ast
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@en
prefLabel
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@ast
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@en
P2093
P2860
P356
P1476
Plasma and intracellular popul ...... ir in HIV-1-infected patients.
@en
P2093
Courtney V Fletcher
Gautam Baheti
Jennifer J Kiser
Peter L Havens
P2860
P304
P356
10.1128/AAC.05317-11
P407
P577
2011-09-06T00:00:00Z